These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 2522336

  • 1. Inhibitory effect of a selective thromboxane A2 receptor antagonist, EP 092, on platelet aggregation in whole blood ex vivo and in vivo.
    Booth RF, Honey AC, Lad N, Tuffin DP, Wade PJ.
    Br J Pharmacol; 1989 Feb; 96(2):395-405. PubMed ID: 2522336
    [Abstract] [Full Text] [Related]

  • 2. A comparative study of the involvement of the prostaglandin H2/thromboxane A2 pathway in intravascular platelet aggregation in guinea-pigs and rats.
    Mallarkey G, Smith GM.
    Br J Pharmacol; 1985 Feb; 84(2):425-30. PubMed ID: 3156648
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets.
    Watts IS, Wharton KA, White BP, Lumley P.
    Br J Pharmacol; 1991 Feb; 102(2):497-505. PubMed ID: 1826620
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The effects of two synthetic glycoprotein IIb/IIIa antagonists, Ro 43-8857 and L-700,462, on platelet aggregation and bleeding in guinea-pigs and dogs: evidence that Ro 43-8857 is orally active.
    Cook NS, Bruttger O, Pally C, Hagenbach A.
    Thromb Haemost; 1993 Nov 15; 70(5):838-47. PubMed ID: 8128443
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The potent inhibition of vapiprost, a novel thromboxane A2 receptor antagonist, on the secondary aggregation and ATP release of human platelets.
    Horie S, Yamada M, Satoh M, Noritake S, Hiraishi S, Kizaki K, Kurusu O, Nakahara T, Ishii H, Kazama M.
    Biol Pharm Bull; 1997 Jun 15; 20(6):625-31. PubMed ID: 9212979
    [Abstract] [Full Text] [Related]

  • 10. Effect of SC 38249, a novel substituted imidazole, on platelet aggregation in vitro and in vivo.
    Lad N, Honey AC, Lunt DO, Booth RF, Westwick J, Manley PW, Tuffin DP.
    Thromb Haemost; 1988 Apr 08; 59(2):164-70. PubMed ID: 3133807
    [Abstract] [Full Text] [Related]

  • 11. [Effect of a new thromboxane A2 antagonist, S-145, on platelet aggregation].
    Kakushi H, Shike T, Uchida K.
    Nihon Yakurigaku Zasshi; 1989 Mar 08; 93(3):171-8. PubMed ID: 2731807
    [Abstract] [Full Text] [Related]

  • 12. ZD1542, a potent thromboxane A2 synthase inhibitor and receptor antagonist in vitro.
    Brownlie RP, Brownrigg NJ, Butcher HM, Garcia R, Jessup R, Lee VJ, Tunstall S, Wayne MG.
    Br J Pharmacol; 1993 Dec 08; 110(4):1600-6. PubMed ID: 8306107
    [Abstract] [Full Text] [Related]

  • 13. The pharmacology of L-670,596, a potent and selective thromboxane/prostaglandin endoperoxide receptor antagonist.
    Ford-Hutchinson AW, Girard Y, Lord A, Jones TR, Cirino M, Evans JF, Gillard J, Hamel P, Leveillé C, Masson P.
    Can J Physiol Pharmacol; 1989 Sep 08; 67(9):989-93. PubMed ID: 2598135
    [Abstract] [Full Text] [Related]

  • 14. Platelet aggregation and fibrinogen binding in human, rhesus monkey, guinea-pig, hamster and rat blood: activation by ADP and a thrombin receptor peptide and inhibition by glycoprotein IIb/IIIa antagonists.
    Cook NS, Zerwes HG, Tapparelli C, Powling M, Singh J, Metternich R, Hagenbach A.
    Thromb Haemost; 1993 Sep 01; 70(3):531-9. PubMed ID: 8259560
    [Abstract] [Full Text] [Related]

  • 15. In vivo effects of a novel thromboxane A2/prostaglandin H2 (TXA2/PGH2) partial agonist, (+)5(Z)-7-[3-endo-phenylsulfonylamino[2.2.1]- bicyclohept-2-exo-yl]-heptenoic acid [(+)-S-145], on vascular, platelet and cardiac function.
    Dubé GP, Jakubowski JA, Brune KA, Bemis KG, Kurtz WL.
    J Pharmacol Exp Ther; 1995 Feb 01; 272(2):799-807. PubMed ID: 7853197
    [Abstract] [Full Text] [Related]

  • 16. Human recombinant phospholipase A2 inhibits platelet aggregation in vitro and in vivo in rat and guinea pig.
    Cirino G, Cicala C, Sorrentino R, Sorrentino L, Browning JL, Page CP.
    Eur J Pharmacol; 1994 Feb 03; 252(2):147-54. PubMed ID: 8157055
    [Abstract] [Full Text] [Related]

  • 17. Pharmacological characterization of FCE 27262, a combined thromboxane synthase inhibitor and PGH2/TXA2 receptor antagonist.
    Vaghi F, Colombo M, Pierucci L, Volpi D, Dho L, Ukmar G, Rosa B, Salvati P.
    Drugs Exp Clin Res; 1993 Feb 03; 19(6):249-60. PubMed ID: 8013268
    [Abstract] [Full Text] [Related]

  • 18. GR32191, a highly potent and specific thromboxane A2 receptor blocking drug on platelets and vascular and airways smooth muscle in vitro.
    Lumley P, White BP, Humphrey PP.
    Br J Pharmacol; 1989 Jul 03; 97(3):783-94. PubMed ID: 2527074
    [Abstract] [Full Text] [Related]

  • 19. Beneficial effects of a new potent and specific thromboxane receptor antagonist (SQ-29,548) in vitro and in vivo.
    Darius H, Smith JB, Lefer AM.
    J Pharmacol Exp Ther; 1985 Nov 03; 235(2):274-81. PubMed ID: 2997428
    [Abstract] [Full Text] [Related]

  • 20. Effects of thromboxane antagonist EP 045 on platelet aggregation.
    Jones RL, Wilson NH, Armstrong RA, Peesapati V, Smith GM.
    Adv Prostaglandin Thromboxane Leukot Res; 1983 Nov 03; 11():345-50. PubMed ID: 6303074
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.